Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Smith Giri, MBBS, Madan R Aryal, MD, Han Yu, PhD, Alyssa Grimshaw, MSLIS, Ranjan Pathak, MD, Scott F. Huntington, MD MPH, Binod Dhakal, MBBS

Blood (2019) 134 (Supplement_1): 2188.

https://doi.org/10.1182/blood-2019-130389

Published: 2019

Journal Articles

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Binod Dhakal, MBBS, Muhammad Umair Mushtaq, MD, Ashley Cunningham, MD, Athanasios Papadas, MD, Adam Pagenkopf, BS, Joshua Wiesner, Catherine Leith, MBBChir, Peiman Hematti, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD, Fotis Asimakopoulos, PhDMBBChir,

Blood (2019) 134 (Supplement_1): 3088.

https://doi.org/10.1182/blood-2019-127565

Published: 2019

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Luciano J. Costa, MD PhD, Saurabh Chhabra, MD, Kelly N. Godby, MD, Eva Medvedova, MD, Robert F. Cornell, MD MS, Aric C. Hall, MD, Rebecca W. Silbermann, MD, Racquel Innis-Shelton, MD, Binod Dhakal, MBBS, Diego DeIdiaquez, MD, Pamela Hardwick, RN, Yelak Biru, James L. Omel, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD

Blood (2019) 134 (Supplement_1): 860.

https://doi.org/10.1182/blood-2019-123170

Published: 2019

Journal Articles

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)

Binod Dhakal, MBBS, Raphael Fraser, PhD, Zhubin Gahvari, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Saurabh Chhabra, MD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD

Blood (2019) 134 (Supplement_1): 783.

https://doi.org/10.1182/blood-2019-126646

Published: 2019

Journal Articles

Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation

Sagar Patel, MD, Saulius K. Girnius, MD, Binod Dhakal, MBBS, Lohith Gowda, MD, Raphael Fraser, PhD, Omar Davila, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Shaji K. Kumar, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD

Blood (2019) 134 (Supplement_1): 266.

https://doi.org/10.1182/blood-2019-127049

Published: 2019

Journal Articles

Use of Intravenous Immunoglobulin G in HIT: Impact on Thrombosis and Mortality in a Population-Based Study

Binod Dhakal, MBBS, Rein Lisa, Aniko Szabo, PhD, Richard H. Aster, MD, Anand Padmanabhan, MD PhD

Blood (2018) 132 (Supplement 1): 2512.

https://doi.org/10.1182/blood-2018-99-117190

Published: 2018

Journal Articles

Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US

Binod Dhakal, MBBS, Smith Giri, MBBS, Adam Levin, MD, Rein Lisa, Timothy S. Fenske, MD, Saurabh Chhabra, MD, Nirav N Shah, MD, Aniko Szabo, PhD, Anita D'Souza, MBBS, Marcelo C. Pasquini, MD, Parameswaran Hari, MBBS, MD, Mehdi Hamadani, MD

Blood (2018) 132 (Supplement 1): 617.

https://doi.org/10.1182/blood-2018-99-116196

Published: 2018

Journal Articles

Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)

Binod Dhakal, MBBS, Anita D'Souza, MBBS, Mehdi Hamadani, MD, Carlos E. Arce-Lara, MD, Katrina Schroeder, Saurabh Chhabra, MD, Nirav N Shah, MD, Katelyn Gauger, Taylor Keaton, Marcelo C. Pasquini, MD, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2018-99-110832

Published: 2018

Journal Articles

Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US

Blood (2018) 132 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2018-99-118873

Published: 2018

Journal Articles

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

Anita D'Souza, MBBS, Kathryn E Flynn, PhD, Binod Dhakal, MBBS, Saurabh Chhabra, MD, Marcelo C Pasquini, MDMS, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2018-99-114783

Published: 2018

Journal Articles

Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States

Guru Subramanian Guru Murthy, MBBS, Ravi Narra, MD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2575.

https://doi.org/10.1182/blood.V130.Suppl_1.2575.2575

Published: 2017

Journal Articles

Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease

Gina Patel, Parameswaran Hari, MD MRCP, MS, Aniko Szabo, PhD, Rein Lisa, Lisa M. Baumann Kreuziger, MD MS, Saurabh Chhabra, MD, Binod Dhakal, MBBS, Anita D'Souza, MBBS

Blood (2017) 130 (Supplement 1): 2363.

https://doi.org/10.1182/blood.V130.Suppl_1.2363.2363

Published: 2017

Journal Articles

Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States

Guru Subramanian Guru Murthy, MBBS, Ravi Narra, MD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2578.

https://doi.org/10.1182/blood.V130.Suppl_1.2578.2578

Published: 2017

Journal Articles

Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study

Saurabh Chhabra, MD, Parameswaran Hari, MD MRCP, MS, Alexis Visotcky, Nirav N Shah, MD, J. Douglas Rizzo, MD, Wael Saber, MD MS, Anita D'Souza, MBBS, Binod Dhakal, MBBS, Ashish Anshu, MS, PhD, Robert Thompson, Timothy S. Fenske, MD, Bronwen E. Shaw, PhD MRCP, FRCPath, William R. Drobyski, MD, Marcelo C. Pasquini, MD, Mehdi Hamadani, MD

Blood (2017) 130 (Supplement 1): 1974.

https://doi.org/10.1182/blood.V130.Suppl_1.1974.1974

Published: 2017

Journal Articles

Using "Big-Data" to Evaluate in-Hospital Morbidity and Mortality in Systemic Light Chain (AL) Amyloidosis after High Dose Therapy and Autologous Stem Cell Transplant (HDT/ASCT)

Binod Dhakal, MBBS, Xinran Qi, Guru Subramanian Guru Murthy, MBBS, Ravi Narra, MD, Aniko Szabo, PhD, Saurabh Chhabra, MD, Anita D'Souza, MBBS, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 2170.

https://doi.org/10.1182/blood.V130.Suppl_1.2170.2170

Published: 2017

Journal Articles

Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT)

Adam Pagenkopf, Binod Dhakal, MBBS, Chelsea L. Hope, PhD, Athanasios Papadas, MD, Michael G Johnson, PhD, Bradley Nagel, Elena Kurudza, Samik Partha, Bianca Ruffolo, Catherine Leith, MBBChir, Shigeki Miyamoto, PhD, Peiman Hematti, MD, Parameswaran Hari, MD MRCP, MS, Natalie Scott Callander, MD, Fotios Asimakopoulos, PhDMBBChir,

Blood (2017) 130 (Supplement 1): 1756.

https://doi.org/10.1182/blood.V130.Suppl_1.1756.1756

Published: 2017

Journal Articles

Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Binod Dhakal, MBBS, Ravi Narra, MD, Timothy Smunt, MBA, Angela Canadeo, Pharm D, Saurabh Chhabra, MD, Anita d'Souza, MBBS, MD, Bishal Gyawali, MD PhD, Parameswaran Hari, MD MRCP, MS, Saroj Niraula, MD

Blood (2017) 130 (Supplement 1): 3403.

https://doi.org/10.1182/blood.V130.Suppl_1.3403.3403

Published: 2017

Journal Articles

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

Attaphol Pawarode, MD, Anita D'Souza, MBBS, Marcelo C. Pasquini, MD, Bryon Johnson, PhD, Thomas Braun, PhD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, John M. Magenau, MD, Nirav N Shah, MD, Mary Mansour Riwes, DO, Brian Parkin, MD, Pavan Reddy, MD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 339.

https://doi.org/10.1182/blood.V130.Suppl_1.339.339

Published: 2017

NARROW

Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)

Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation

Use of Intravenous Immunoglobulin G in HIT: Impact on Thrombosis and Mortality in a Population-Based Study

Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US

Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)

Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States

Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease

Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States

Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study

Using "Big-Data" to Evaluate in-Hospital Morbidity and Mortality in Systemic Light Chain (AL) Amyloidosis after High Dose Therapy and Autologous Stem Cell Transplant (HDT/ASCT)

Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT)

Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only